Advancing Care in Non-Clear Cell RCC: Optimizing ICI and TKIs
Released On
April 30, 2025
Expires On
April 29, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Oncology, Urology
Topic(s)
Oncology
Providers/Grant Support
Provided by The France Foundation and The Kidney Cancer Association
This activity is supported by independent medical education grants from Eisai, Exelixis, and Merck.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Nursing Contact Hour
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of oncologists, urologists, nurse practitioners, and other health care professionals involved in the management of patients with nccRCC.
Program Overview
This activity is designed to educate the multidisciplinary care team on the latest advances in the diagnosis and treatment of nccRCC. Expert faculty will discuss ways to promote best practices for communicating with care team members and patients by using case-based scenarios to deliver key points.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Recall the importance of accurate diagnosis and classification of nccRCC
- Compare and contrast clinical trial data on current and emerging uses of ICIs, TKIs, and combination ICI/TKI therapy
- Describe the rationale for combination therapies and treatment sequencing strategies in nccRCC
- Identify approaches for monitoring and managing AEs associated with ICIs and TKIs in nccRCC
Faculty
Pedro Barata, MD, MSc, FACP
Miggo Family Chair in Cancer Research
Co-Leader Genitourinary (GU) Disease Team
Director of GU Medical Oncology Research Program
University Hospitals Seidman Cancer Center
Associate Professor of Medicine
Case Western Reserve University
Case Comprehensive Cancer Center
Cleveland, OH
Sumanta K. Pal, MD, FASCO
Professor & Vice Chair of Academic Affairs
Department of Medical Oncology & Experimental Therapeutics
City of Hope Comprehensive Cancer Center
Duarte, CA
Accreditation Statement
In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team..
Credit Designation
Physicians
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The France Foundation designates this activity for 1.0 contact hour.
All other health care professionals completing this course will be issued a statement of participation.
Disclosures of Conflicts of Interest
- Pedro Barata, MD, MSc, FACP
- Non-CE Consulting Relationship: Astellas, AstraZeneca, Bayer, BMS, Caris Life Sciences, Dendreon, EMD Serono, Eisai, Exelixis, Guardant Health, Ipsen, Janssen, Myovant, OncLive, Pfizer, Seattle Genetics, Targeted Oncology, UroToday
- Non-CE Speakers Bureau Relationship: Astellas
- Contract Research Relationship: Allogene Therapeutics, CRISPR Therapeutics, Eisai, Genentech/F. Hoffmann–LA Roche Ltd., Pfizer
- Sumanta Pal, MD, FASCO
- Non-CE Consulting Relationship: Astellas, AstraZeneca, Bayer, BMS, Caris Life Sciences, Dendreon, EMD Serono, Eisai, Exelixis, Guardant Health, Ipsen, Janssen, Myovant, OncLive, Pfizer, Seattle Genetics, Targeted Oncology, UroToday
- Contract Research Relationship: Allogene Therapeutics, CRISPR Therapeutics, Eisai, Genentech/F. Hoffmann–LA Roche Ltd., Pfizer
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures
- Participate in the online activity
- Submit the evaluation form
Certificates will be emailed to participants.
Course Viewing Requirements
Supported Browsers (Desktop/Mobile)
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Disclaimer
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.
Contact Information
For CME questions, please contact: [email protected].